

B<sub>2</sub> (13) (Amended) The method of claim 9, wherein said thrombospondin compound is thrombospondin-2.

---

(14) The method of claim 11, wherein said camptothecin compound is irinotecan (CPT-11).

(15) The method of claim 11, wherein said camptothecin compound is topotecan.

16. The method of claim 11, wherein said camptothecin compound is selected from the group consisting of 20-S-camptothecin (20(S)CPT), 10,11-methylenedioxy-CPT (10,11-CPT), 7-ethyl-10-hydroxy-CPT (SN38), and 9-AC<sup>3</sup>.

17. The method of claim 9, wherein said mammal is a <sup>3</sup>human.

---

18. (Amended) The method of claim 9, wherein said thrombospondin compound is administered prior to said inhibitor of DNA topoisomerase I enzyme activity.

B<sub>3</sub> (19) (Amended) The method of claim 9, wherein said inhibitor of DNA topoisomerase I enzyme activity is administered prior to said thrombospondin compound. ✓

(20) (Amended) The method of claim 9, wherein said thrombospondin compound and said inhibitor of DNA topoisomerase I enzyme activity are administered simultaneously.

---